The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
James Brugarolas
Honoraria - MDoutlook; Regeneron; Regeneron
Consulting or Advisory Role - Regeneron
Research Funding - Genentech/Roche (Inst); ImaginAb (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - Licensed to Bethyl: MONOCLONAL ANTIBODY AGAINST HUMAN REDD1 PROTEIN THAT (1) RECOGNIZES BOTH HUMAN AND MOUSE PROTEINS (POSSIBLY OTHER SPECIES) AND (2) RECOGNIZES THEM BY BOTH WESTERN BLOT AND IMMUNOPRECIPITATION (Inst); U.S. Application Number: 19/083,289 mTORC1 inhibition of non-tumor cells is necessary for rapalog anti-tumor activity in renal cancer (Inst); U.S. Application Number: 63/766,832 Therapeutic Potential of HIF-2a Inhibition for Paraneoplastic Hypercalcemia in Renal Cell Carcinoma (Inst); U.S. Application Numbers: 12,161,618 and 11,576,889 METHODS OF IDENTIFYING AND TREATING PATIENTS WITH HIF-2 INHIBITOR RESISTANCE (Inst); U.S. Application Numbers: 17/153,128 and 17/129,352 PET RADIOPHARMACEUTICALS FOR NON-INVASIVE EVALUATION OF HIF-2alpha (Inst); U.S. Application Numbers: US 12,234,516 and 18/965,965 BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF (Inst)
Travel, Accommodations, Expenses - DAVA Pharmaceuticals; DAVA Pharmaceuticals
 
Pooja Ghatalia
Consulting or Advisory Role - Merck
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Merck (Inst)
 
Saby George
Consulting or Advisory Role - AstraZeneca; AVEO; AVEO; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; GlaxoSmithKline; Johnson & Johnson/Janssen; Merck; Novartis; Pfizer; Sanofi; Seattle Genetics/Astellas
Research Funding - Agensys (Inst); Aravive (Inst); Aveo (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Medarex; Sanofi
 
John Haanen
Stock and Other Ownership Interests - Neogene Therapeutics
Consulting or Advisory Role - Achilles Therapeutics (Inst); AstraZeneca (Inst); bioNTech (Inst); Bristol-Myers Squibb (Inst); CureVac; Eisai (Inst); Immunocore (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Ipsen (Inst); Molecular Partners (Inst); MSD Oncology (Inst); Neogene Therapeutics; Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Sastra Cell Therapy; T-Knife (Inst); Third Rock Ventures; Third Rock Ventures (Inst)
Research Funding - Amgen (Inst); Asher Biotherapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Howard Gurney
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck Serono; Merck Sharp & Dohme; Pfizer; Roche
Speakers' Bureau - Astellas Pharma; AstraZeneca; Ipsen; Merck Serono
 
Rahul Ravilla
Stock and Other Ownership Interests - Exelixis; Pfizer
Consulting or Advisory Role - Pfizer/Astellas
Speakers' Bureau - Bristol-Myers Squibb/Celgene; Exelixis; Johnson & Johnson/Janssen; Merck; Pfizer/Astellas
Research Funding - McKesson
 
Astrid Van Der Veldt
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); GE Healthcare (Inst); Ipsen (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Ipsen (Inst)
 
Benoit Beuselinck
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck KGaA (Inst); Pfizer (Inst)
Speakers' Bureau - Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck (Inst); Pfizer (Inst)
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Ipsen (Inst); Pfizer (Inst)
 
Ilya Pokataev
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Eisai; Merck; Novartis; Pfizer; Pierre Fabre; Roche; Swixx BioPharma
 
Britt Suelmann
No Relationships to Disclose
 
Mark Tuthill
Honoraria - Eisai
Consulting or Advisory Role - Gilead Sciences; Novartis; Oxford VacMedix; Roche; Seagen
Speakers' Bureau - Bayer; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Seagen
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - Merck; Novartis
 
Daniel Vaena
Honoraria - HMP; Medical Education Consortium; OncLive; Total Health Conferencing
Consulting or Advisory Role - Aptitude Health; Astellas Pharma; AstraZeneca; Avyxa; Bayer; Cardinal Health; Clinical Education Alliance; Curio/Vaniam Group; DAVA Pharmaceuticals; EMD Serono; Exelixis; Gilead Sciences; IDEOlogy Health; IntrinsiQ; Janssen; MJH Life Sciences; Revolution Medicines; Sanofi; Seagen
Research Funding - ALX Oncology (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Eikon (Inst); Exelixis (Inst); Merck (Inst); OBI Pharma (Inst); Roche/Genentech (Inst); Seagen (Inst); Tallac Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst)
 
Yiwei Zhang
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Chen-hua Chuang
Employment - Merck
Stock and Other Ownership Interests - Abbvie; Amgen; Merck
 
Amir Vajdi
Employment - Dana Farber Cancer Hospital; Merck
Stock and Other Ownership Interests - Merck
 
Andrey Loboda
Employment - Merck; Merck
Stock and Other Ownership Interests - Merck
 
Rodolfo Perini
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Jaime Merchan
Consulting or Advisory Role - Merck
Research Funding - Arcus Biosciences (Inst); BioNTech (Inst); Corvus Pharmaceuticals (Inst); DynamiCure Biotechnology (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); IMUGENE (Inst); Kalivir Immunotherapeutics (Inst); Merck (Inst); ModeX Therapeutics Inc (Inst); Peloton Therapeutics (Inst); Replimune (Inst); Rubius Therapeutics (Inst); Seattle Genetics/Astellas (Inst); Sillajen (Inst); Tizona Therapeutics, Inc. (Inst); Tocagen (Inst); Trishula Therapeutics (Inst); Tubulis GmbH (Inst); Vyriad (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Michael Atkins
Leadership - Werewolf Therapeutics
Stock and Other Ownership Interests - Pyxis; Werewolf Pharma
Consulting or Advisory Role - Abbvie; Agenus; AstraZeneca; Aveo; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Delcath Systems; Eisai; Exelixis; Genentech; Handa Oncology; Innovent Biologics; IO Biotech; Jazz Pharmaceuticals; Merck; Novartis; Oncorena; Pfizer; Pliant; Pyxis; Replimune; SeaGen; Simcha Therapeutics; Syncona; Werewolf Pharma
Research Funding - Agenus (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - BMS Canada; BMS Sweden